Tissue Regenix reported a proposed acquisition of CellRight Technologies.
Here are four notes:
1. CellRight Technologies boasts an orthopedic portfolio with human-derived bone graft products.
2. Tissue Regenix develops soft tissue products featuring its patented decellularisation dCELL Technology.
3. Tissue Regenix would leverage CellRight Technologies' San Antonio-based tissue bank, opening a door to the U.S. market.
4. The proposed acquisition would allow Tissue Regenix to enter the U.S. orthopedics market by 2018, honing in on ligament reconstruction.